Feksine

Quick links to important sections

Feksine

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Feksine

Quick Facts

Property Description
Active ingredient Fexofenadine Hydrochloride (Fexofenadine HCl)
Form Tablet, Capsule, Oral Suspension (Liquid)
Pharmacological class Second-Generation Antihistamine (H1-Receptor Antagonist)
Common use Symptomatic relief of allergic conditions
Origin Synthetic
Non-sedating status Classified as non-sedating due to minimal BBB penetration

Feksine: Defining Its Identity and Composition

Feksine is a medicinal product whose active component is Fexofenadine Hydrochloride (Fexofenadine HCl), a compound belonging to the class of second-generation antihistamines. The active ingredient is a chemically synthesized organic compound used for systemic relief, primarily available in solid oral dosage forms such as tablets and capsules, as well as liquid oral suspensions. The product is fundamentally a single-entity product (monotherapy), meaning its primary therapeutic action derives solely from the Fexofenadine component. It may also be formulated with a decongestant, such as Pseudoephedrine, for combination use, but its core identity remains rooted in the Fexofenadine active ingredient.


What Pharmacological Class Does Feksine Belong To?

Feksine belongs to the Second-Generation Antihistamine class of medicines, functioning as a selective H1-Receptor Antagonist. This classification is critical because Fexofenadine is engineered to have minimal ability to penetrate the blood-brain barrier (BBB), which is the unique factor that distinguishes it from older antihistamines. By predominantly targeting receptors in the periphery of the body, Feksine is categorized as a non-sedating agent. This selective action minimizes central nervous system effects, a characteristic clinically recognized for supporting routine daily activities without impairment. This lack of sedative properties is a key differentiation point compared to first-generation agents.


General Purpose and Therapeutic Role of Fexofenadine

The primary therapeutic purpose of Feksine is to provide effective, systemic management by controlling symptoms that arise from the body's allergic response. Its role is to mitigate the discomfort and physical manifestations associated with the release of the key mediator histamine in the body. By consistently blocking the action of histamine at the receptor level, Feksine supports improved patient comfort and helps maintain normal daily function during periods of allergic activity. For instance, the drug is typically used to provide relief during peak seasonal allergy periods when exposure to environmental allergens is unavoidable. It provides relief against general symptoms stemming from various common environmental or chronic allergic conditions.

What side effects are possible with Feksine?

Possible Side Effects and Safety Information

The safety profile for Feksine (Fexofenadine Hydrochloride) is officially documented by government regulatory bodies, detailing adverse reactions by frequency and physiological system. This information is classified to ensure a neutral and medically grounded understanding of possible effects.

Frequency and System-Organ Classes

The most Common adverse reactions documented in regulatory sources primarily involve the Nervous System and General disorders. These frequently observed effects include headache, drowsiness, dizziness, nausea, and fatigue. Events such as insomnia, nervousness, sleep disorders/nightmares, diarrhea, and dyspepsia have also been reported, generally categorized from Post-marketing Experience or Not Known frequency.

Rare, but medically significant, reactions affect the Cardiac System (e.g., tachycardia and palpitations) and the Immune System.

Serious Adverse Reactions

The official labeling documents rare but serious manifestations of systemic Hypersensitivity Reactions. These include severe events such as anaphylaxis (a systemic, life-threatening reaction) and angioedema (swelling of the face, lips, or tongue), requiring prompt medical attention as defined by official regulatory safety standards.

Population-Specific Safety Considerations

Specific safety considerations are defined for populations where the drug's clearance may be altered. For individuals with Renal Impairment (decreased kidney function), a lower starting dose is often advised in the regulatory texts due to reduced clearance and potential for increased drug concentrations. Conversely, official documents typically state that no dose adjustment is required for patients with Hepatic Impairment as the drug undergoes minimal liver metabolism.

Safety Restrictions and Limitations

The absorption and efficacy of Feksine can be restricted by co-administration with other products. Concomitant use with aluminum or magnesium-containing antacids may reduce the drug's absorption. Furthermore, the bioavailability of Fexofenadine is decreased when consumed with fruit juices (such as apple, orange, or grapefruit juice), a note included in the official safety literature.

Overdose and Emergency Response

The official regulatory data on Fexofenadine overdose consistently documents the clinical presentation as primarily involving dizziness, drowsiness (somnolence), and dry mouth (xerostomia). Although high-dose studies suggest low acute toxicity, the potential for serious class-related cardiovascular effects, such as tachycardia or cardiac arrhythmia, requires the administration to be done with care in those with heart conditions.


Documented Manifestations and Required Action

Domain Regulatory Statement
Documented Manifestations Dizziness, Drowsiness, Dry mouth (reported with overdose)
Immediate Action Mandated Seek emergency medical attention or contact a Poison Control Center right away.

In the event of a suspected overdose, regulatory authorities mandate that immediate medical attention must be sought. Patients are instructed to contact emergency services or a Poison Control Center right away. The management of Fexofenadine overdose is defined as symptomatic and supportive treatment because no specific antidote is known.

Procedures to remove unabsorbed medicine, such as the administration of activated charcoal, should be considered, though haemodialysis does not effectively remove the compound. Special considerations are noted for managing overdose in specific populations: data are limited for older people and for patients with renal or hepatic impairment, where the drug's elimination may be prolonged. Cardiac monitoring may be necessary for large acute exposures.

Therapeutic Uses of Feksine

Main Uses of Feksine

Feksine is an antibiotic medication belonging to the cephalosporin class. It is primarily used to treat a variety of bacterial infections by interfering with the formation of the bacterial cell wall, which leads to the eventual destruction of the bacteria.

Common indications for this medication include:

  • Respiratory Tract Infections: This includes conditions such as pneumonia, acute bronchitis, and infected bronchiectasis.
  • Ear, Nose, and Throat Infections: It is frequently prescribed for otitis media (middle ear infection), sinusitis, tonsillitis, and pharyngitis.
  • Urinary Tract Infections: Feksine is effective against certain bacteria that cause infections in the bladder and kidneys, such as cystitis and pyelonephritis.
  • Skin and Soft Tissue Infections: It may be used to treat bacterial infections of the skin, including abscesses, cellulitis, and infected wounds.
  • Other Bacterial Infections: It is sometimes used for dental infections and certain bone or joint infections when caused by susceptible organisms.

Benefits and Clinical Action

The primary benefit of Feksine is its broad-spectrum activity, meaning it is effective against a wide range of both Gram-positive and Gram-negative bacteria.

Targeted Action

Feksine acts specifically on bacterial cells. Because human cells do not have cell walls, the medication is designed to target the bacteria without affecting the host's cells in the same manner. This targeted approach helps in resolving the physical symptoms of infection, such as fever, pain, and inflammation.

Efficacy in Recovery

By halting the growth and spread of the pathogen, Feksine assists the body's natural immune system in clearing the infection more efficiently. Clinical use has shown that appropriate application of the medication leads to a significant reduction in the duration of illness and helps prevent the progression of the infection into more severe systemic conditions.

Regulatory References

  1. NIH MedlinePlus overview on Fexofenadine

Eligibility and Restrictions for Use

Feksine (Fexofenadine HCl) eligibility is determined by specific regulatory constraints related to age, physiological status, and underlying health conditions, as documented by official government sources.

Populations Excluded or Restricted

Classification Population or Condition
Absolute Contraindication Patients with known hypersensitivity to Fexofenadine or any excipient.
Not Recommended/Restricted Pregnancy (use only if clearly necessary/benefit outweighs risk).
Breastfeeding mothers (not recommended as Fexofenadine is excreted in breast milk).
Patients with renal impairment (requires caution and potential dose adjustment).
Use Not Established Infants younger than 6 months of age for any labeled use.

Age-Specific Eligibility

Feksine is approved for use in adults and adolescents (12 years). For children, eligibility varies by formulation and indication: 6 months and older may use the oral suspension for chronic hives, while tablets are typically approved for children 6 years. Older adults (65 years) require caution due to the higher likelihood of age-related kidney function decline, which affects drug clearance. Certain formulations, such as Orally Disintegrating Tablets, are restricted for patients with Phenylketonuria (PKU) if they contain phenylalanine.

What should I know about interactions with other medicines?

The official interaction profile of Feksine (Fexofenadine Hydrochloride) is primarily defined by how other substances affect the drug’s systemic exposure and bioavailability through modulation of drug transport systems. The minimal metabolism of Fexofenadine means interactions are typically classified as pharmacokinetic rather than enzyme-mediated.

Interaction Scope

Category Official Regulatory Statement
Medicinal product categories with documented interactions Aluminum- and magnesium-containing antacids; P-glycoprotein ( P-gp) and Organic Anion Transporting Polypeptide ( OATP) inhibitors.
Specific interacting medicines (if explicitly listed) Erythromycin, Ketoconazole, Aluminum hydroxide/Magnesium hydroxide combination antacids.
Mechanistic basis of interactions (only if stated in label) Pharmacokinetic interaction involving drug transport systems (P-gp efflux and OATP uptake transporters).
Timing-based interaction rules (if applicable) Co-administration with aluminum- and magnesium-containing antacids must be separated in time, with regulatory documents often advising a separation of at least 2 hours.
Population-specific interaction notes (if applicable) A significant increase in Fexofenadine plasma exposure ( AUC and C max) is documented in patients with moderate to severe renal impairment.

Official Interaction Statements

  • Co-administration of the P-gp inhibitors Erythromycin and Ketoconazole is documented to significantly increase Fexofenadine systemic exposure, resulting in a 2- to 3-fold increase in plasma levels.
  • The co-administration of aluminum- and magnesium-containing antacids results in a significant reduction in Fexofenadine systemic exposure and bioavailability.
  • Fexofenadine administration with certain Fruit Juices (grapefruit, orange, and apple) is documented to reduce bioavailability and systemic exposure due to the inhibition of OATP uptake transporters.

Connection to the overall interaction profile: Regulatory documents define the Feksine interaction structure as depending on drug transport systems, classifying substances as those that either officially increase exposure via P-gp inhibition or those that officially decrease exposure via impaired absorption, which requires specific timing-based administration constraints with certain products.

Mechanism of Action

Feksine functions as a selective peripheral histamine H1 receptor antagonist. Following systemic absorption, the compound distributes to various effector cells, including those in the gastrointestinal tract, blood vessels, and respiratory tract. Feksine binds reversibly to the H1 receptor, acting as an inverse agonist to stabilize its inactive conformation.

This binding event competitively blocks the activation of the receptor by endogenous histamine. Intracellularly, this inhibition prevents the G q-mediated signaling cascade, including the downstream activation of phospholipase C and subsequent rise in intracellular Ca^2+ concentration, which is typically triggered by histamine.

Downstream, Feksine modulates cellular release of various pro-inflammatory mediators, including leukotrienes (LTC4, LTD4, LTE4), prostaglandins (PGE2, PGF2alpha), and specific cytokines (e.g., ICAM-1). System-level physiological consequences include the modulation of peripheral tissue vascular permeability and vasodilation, as well as the regulation of smooth muscle contraction in the respiratory and gastrointestinal systems. The compound minimally crosses the blood-brain barrier.

Dosage and Administration Information

How to Use Feksine

Feksine, which contains the active ingredient Fexofenadine Hydrochloride, is administered orally. It is available in various forms, including tablets, capsules, and oral suspension. The usage protocol depends on the frequency of administration, the patient's age, and specific health conditions.


Standard Dosing and Administration Frequency

Administration follows either a once-daily (QD) or a twice-daily (BID) schedule, depending on the dosage and the condition being managed.

  • Adults and children (12 years and older): The standard dosage is typically 60 mg twice daily or 180 mg once daily.
  • Children (6 to 11 years): The typical regimen is 30 mg twice daily.

For chronic conditions, Feksine may be used continuously, while for seasonal symptoms, use may be intermittent.


Administration Requirements and Restrictions

Tablets and capsules should be taken with water. Intake must be separated from certain substances that can impair the body's ability to absorb the medication. Fexofenadine should not be taken with fruit juices, such as grapefruit, apple, or orange juice.

Furthermore, administration must be separated from antacids containing aluminum or magnesium. It is recommended to wait between 15 minutes and 2 hours between taking an antacid and Feksine, as these products can significantly reduce the medicine’s effectiveness.


Population-Specific Use

A dose reduction is recommended for patients with decreased renal function:

  • Adults and children (12 years and older) with renal impairment: The starting dose is generally adjusted to 60 mg once daily.
  • Children (6 to 11 years) with renal impairment: The dose is typically reduced to 30 mg once daily.

If a dose is missed, the next dose should be taken at the regularly scheduled time. A double dose should not be taken to compensate for a missed one.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Feksine

Evidence for Use in Seasonal and Perennial Allergic Rhinitis (SAR/PAR)

Research for Feksine used in exploring allergic rhinitis—often called hay fever—has been established primarily upon short-term randomized controlled trials (RCTs). These types of studies are applied in research exploring how symptoms change over time and are a study type used to rigorously examine symptom patterns. Researchers used standardized measures, such as the Total Symptom Score (TSS), in trials involving adults, adolescents, and children. The study outcomes examined focused on quantifying changes in both the nasal symptoms (like sneezing and runny nose) and ocular symptoms (like itchy or watery eyes), and were used to monitor whether changes in nasal and ocular symptoms occurred during the study period.

Studies conducted during periods of increased symptom activity reported how symptoms evolved in the observed populations. Research highlights changes measured during the study period for outcomes related to systemic or functional imbalance linked to allergic symptoms.

Evidence for Use in Chronic Hives (Chronic Idiopathic Urticaria)

For the exploration of Feksine’s application in chronic hives, or Chronic Idiopathic Urticaria (CIU), the compound was evaluated in short-term, randomized, placebo-controlled clinical trials. The research focused on conditions characterized by fluctuating or episodic manifestations, specifically examining how symptoms changed during acute or disruptive episodes. Research examined outcomes related to physical discomfort, such as the severity of pruritus (skin itching), and the number and size of wheals (hives), combined into a Total Symptom Score for urticaria. Studies report how symptoms evolved in the observed populations, contributing to the broader evidence landscape for managing symptoms linked to inflammatory or irritative states.

Long-Term Evidence and Follow-Up Duration

The majority of research for Feksine focuses on short-term symptom patterns, meaning studies exploring short-term symptom changes over periods such as two to four weeks. While these short-term studies are relevant in trials assessing short-term or episodic symptom patterns, there is limited information for long-term outcomes that would capture the full impact of treatment over many months or years. Studies that extend beyond the typical short-term duration are often focused on monitoring safety and tolerability rather than long-term symptom patterns. Therefore, data for long-term outcomes are not fully established.

Evidence in Special Populations

Feksine was evaluated in studies that include different age groups, such as adults, adolescents, and children. Research has explored this compound in pediatric populations with allergic rhinitis and chronic hives. Research related to the youngest pediatric group (ages six months to five years) may involve smaller studies and appears to rely on bridging data from older patients. Data for certain groups, such as those with existing comorbidities or those who are pregnant, remain insufficient, and the results apply only to the populations studied in the key regulatory trials.

Research Gaps and Areas of Uncertainty

The research landscape highlights several areas where data are still emerging or where the evidence is limited. The most notable limitation is the focus on short-term outcomes, meaning data for long-term outcomes for continuous or chronic use remain insufficient. In addition, comparative evidence, such as findings detailing symptom patterns measured against all other second-generation agents, is often mixed or inconsistent across studies. Subgroup findings are uncertain for specific populations.

Frequently Asked Questions (FAQ)

Common questions about Feksine (FAQ)

Q: How quickly do people typically expect Feksine to start working?

Studies and official information indicate that the antihistaminic effect of Feksine typically begins within one hour of administration. The maximum effect is usually seen around six hours after the dose is taken. Official product information describes the effect of a single dose as lasting approximately 24 hours.

Q: What are the rules regarding Feksine and consuming alcohol?

The official labeling for Feksine does not typically include a specific warning or contraindication regarding the consumption of alcohol. Feksine is categorized as a non-sedating antihistamine, which suggests it is less likely to cause central nervous system impairment than older agents.

Q: Is Feksine known to cause weight changes (gain or loss)?

According to the official regulatory safety data, weight changes (gain or loss) are not documented among the common or frequently reported adverse reactions for Feksine. The safety profile focuses on other effects, such as headache, dizziness, and fatigue.

Q: Are there any warnings about driving or operating machinery while taking Feksine?

Official information states that Feksine is unlikely to impair the ability to drive or operate machinery, largely because it has minimal effects on the central nervous system. However, regulatory bodies recommend that individuals observe their own response to the medication before performing tasks that require concentration.

Q: What is the general duration of Feksine treatment?

The documented duration of use for Feksine is based on the condition being addressed. For example, studies examining seasonal allergic rhinitis (hay fever) often follow patients throughout the relevant allergy season. For chronic hives, treatment courses examined in clinical research often span periods up to six weeks.

Q: Are there any common lifestyle factors that impact how Feksine works?

Official regulatory documents explicitly state that Feksine should not be taken at the same time as certain fruit juices, specifically grapefruit, apple, or orange juice. This restriction is noted because these juices can reduce the amount of the medicine that the body is able to absorb.

Q: Why is Feksine sometimes taken only for a short period?

Official documentation indicates that Feksine is sometimes used for short, intermittent periods. This pattern of use is typically for managing temporary or seasonal flare-ups of allergic symptoms. Conversely, for chronic conditions, continuous use may be indicated.

Q: Is it possible for Feksine to become less effective over a long period?

The lack of reported tolerance (the potential for the medicine to become less effective) in clinical trials for up to 28 days suggests that the antihistaminic effect is maintained over that period.

Q: Are there specific symptoms that indicate Feksine might not be right for someone?

Official regulatory safety information lists specific, rare symptoms that may indicate a serious reaction to Feksine. These include signs of a systemic hypersensitivity reaction such as swelling of the face, lips, or tongue (angioedema), or trouble breathing (anaphylaxis). These serious events are defined in official documents as requiring immediate medical review.

Q: What level of research support does Feksine have?

The research supporting Feksine's uses is primarily based on short-term randomized controlled trials (RCTs). These studies examined the drug's effect on symptoms associated with seasonal allergic rhinitis and chronic hives. Official documents note that evidence for long-term outcomes remains limited.

Q: What official information is available about Feksine's use during pregnancy?

Official documentation states that Feksine is generally not recommended for use during pregnancy. Use is restricted to situations where the prescriber has determined that the potential benefit to the patient outweighs any potential risk to the developing fetus.

Q: Does Feksine need to be stored in a special way?

Regulatory documents advise storing Feksine at a controlled room temperature, typically below 30 C (or 86 F). Like most medicines, it must be protected from excessive light and moisture to maintain its integrity.

Q: Is Feksine considered a 'high-risk' medicine by health authorities?

Official regulatory review has classified some formulations of Feksine as suitable for general sale, meaning they can be used safely without mandatory medical supervision. This classification is based on regulatory assessment that the drug is manageable for general sale when used according to label instructions.

Q: Is Feksine a type of medicine that needs frequent monitoring?

The regulatory classification of Feksine suggests that it is not typically a medicine that requires frequent laboratory monitoring or specific ongoing investigation of its effects. This is reflected by its well-established safety profile, which has been reviewed against regulatory criteria.

Q: How does Feksine interact with common pain relievers?

Official guidance documents confirm that Feksine can be taken concurrently with common over-the-counter pain relievers, such as paracetamol (acetaminophen) and ibuprofen. These substances are not typically listed among the medicines known to have a documented pharmacokinetic interaction with Feksine.

Q: What should I do if I suspect an interaction between Feksine and another medication?

Official patient information consistently advises seeking professional guidance from a doctor or pharmacist with any concerns about potential medication interactions.

Q: If I feel better, can I stop taking Feksine on my own?

Official patient guidance advises individuals to consult with a healthcare professional regarding the duration of use for Feksine. A healthcare professional can provide guidance on the appropriate duration of use, as the medicine may be prescribed for intermittent or continuous use.

Q: What happens if I miss a scheduled time to take Feksine?

Official patient instructions advise that if a scheduled dose of Feksine is missed, the patient should skip that dose entirely. The next dose should be taken at the usual time. Instructions advise against taking two doses at once to compensate for a missed one.

Q: Can Feksine be taken with herbal remedies like St. John's Wort?

Official interaction profiles note that the herbal remedy St. John's Wort has been examined for its potential to alter Feksine’s systemic exposure. This is due to its documented effect on certain drug transport systems in the body, although the overall clinical significance of this interaction is generally considered unknown.

How should Feksine be stored and disposed of?

How to Store and Dispose of Feksine?

Official Storage and Handling Requirements

All medicines, including Feksine, must be stored out of the sight and reach of children and pets and should be kept in their original container to maintain integrity. In the absence of specific drug labeling, follow general storage principles to protect the medicine from extreme heat or moisture. Check the prescription label for any specific instructions regarding temperature, light, or special handling constraints.


Official Disposal Instructions

When disposing of unused or expired Feksine, the officially documented recommendation is to prioritize using authorized medicine take-back programs. If a take-back option is unavailable, the regulatory protocol for household trash disposal must be followed. This procedure mandates mixing the medicine with an unappealing substance, such as used coffee grounds or cat litter, placing the mixture in a sealed container, and discarding it in the household trash. Before disposal, remove or scratch out all identifying personal information from the label and packaging.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Feksine found in:

A-Z Index: